<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="8957"><DrugName>Indium In 111 pentetreotide</DrugName><DrugNamesKey><Name id="42997265">Indium In 111 pentetreotide</Name><Name id="42759479">OctreoScan</Name><Name id="42860942">SomatoTher</Name><Name id="42772968">VesCan</Name></DrugNamesKey><DrugSynonyms><Name><Value>OctreoScan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>111In-pentetreotide</Value></Name><Name><Value>MP-1727</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VS-101, Mallinckrodt Medical/Sandoz</Value></Name><Name><Value>VesCan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>SomatoTher</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>pentetreotide-[111In]</Value></Name><Name><Value>Indium111-pentetreotide</Value></Name><Name><Value>Indium In 111 pentetreotide</Value><Types><Type>USAN</Type></Types></Name><Name><Value>DTPA-octreotide-[111In]</Value></Name><Name><Value>139096-04-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24514">Sandoz AG</CompanyOriginator><CompaniesPrimary><Company id="17104">IMCERA Group Inc</Company><Company id="22616">FUJIFILM Toyama Chemical Co Ltd</Company><Company id="17122">Mallinckrodt Medical</Company><Company id="1085756">Mallinckrodt plc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="8957" type="Drug"><TargetEntity id="185370" type="siDrug">[111In]Pentetreotide</TargetEntity></SourceEntity><SourceEntity id="1085756" type="Company"><TargetEntity id="5038068684" type="organizationId">Mallinckrodt Plc</TargetEntity></SourceEntity><SourceEntity id="17104" type="Company"><TargetEntity id="4295904471" type="organizationId">Mallinckrodt LLC</TargetEntity></SourceEntity><SourceEntity id="17122" type="Company"><TargetEntity id="4295904471" type="organizationId">Mallinckrodt LLC</TargetEntity></SourceEntity><SourceEntity id="22616" type="Company"><TargetEntity id="4296625629" type="organizationId">Fujifilm Toyama Chemical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="24514" type="Company"><TargetEntity id="5000685142" type="organizationId">Sandoz AG</TargetEntity></SourceEntity><SourceEntity id="1128" type="ciIndication"><TargetEntity id="C7A" type="ICD10"/><TargetEntity id="209" type="ICD9"/><TargetEntity id="10052399" type="MEDDRA"/><TargetEntity id="D018358" type="MeSH"/><TargetEntity id="-1333045072" type="omicsDisease"/><TargetEntity id="1422" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Neuroendocrine tumor - EU - Jun-1994</FirstLaunched><FirstLaunched>Neuroendocrine tumor - US - Jun-1994</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1128">Neuroendocrine tumor</Indication></IndicationsPrimary><ActionsSecondary><Action id="4158">MRI imaging agent</Action><Action id="5720">Radiodiagnostic</Action><Action id="7212">Endocrine diagnostic agent</Action><Action id="7220">Neoplasm diagnostic agent</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="724">Radiolabeling</Technology><Technology id="731">Imaging</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>T1G</Code><Name>RADIODIAGNOSTIC AGENTS</Name></Ephmra><Ephmra><Code>T1E</Code><Name>MRI AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-31T10:45:47.000Z</LastModificationDate><ChangeDateLast>2018-10-10T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;OctreoScan (injectable) is a 111-In-labelled peptide based tumor imaging agent developed by &lt;ulink linkID="17122" linkType="Company"&gt;Mallinckrodt Medical&lt;/ulink&gt;. The agent targets primary and metastatic neuroendocrine tumors that express somatostatin receptors [&lt;ulink linkID="169034" linkType="reference"&gt;169034&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 1994, the drug was approved in the Czech Republic and was subsequently launched [&lt;ulink linkID="1447334" linkType="Reference"&gt;1447334&lt;/ulink&gt;], [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In June 1994, the drug has been launched in both Europe and the US [&lt;ulink linkID="205584" linkType="reference"&gt;205584&lt;/ulink&gt;]. In March 1995, the drug was launched in France [&lt;ulink linkID="1351494" linkType="Reference"&gt;1351494&lt;/ulink&gt;]. In June 1995, the drug was approved in Ireland and was subsequently launched [&lt;ulink linkID="1398753" linkType="Reference"&gt;1398753&lt;/ulink&gt;]; at that time, the drug was approved in Denmark and was subsequently launched [&lt;ulink linkID="1426868" linkType="Reference"&gt;1426868&lt;/ulink&gt;]. In March 1997, the drug was launched in Switzerland [&lt;ulink linkID="1597316" linkType="Reference"&gt;1597316&lt;/ulink&gt;]. In November 1999, the drug was launched in Norway [&lt;ulink linkID="1458153" linkType="Reference"&gt;1458153&lt;/ulink&gt;]. In February 2006, the agent was approved in Belgium [&lt;ulink linkID="1449892" linkType="Reference"&gt;1449892&lt;/ulink&gt;]. In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1387664" linkType="Reference"&gt;1387664&lt;/ulink&gt;]. In October 2008, the drug was approved in Malta [&lt;ulink linkID="1452893" linkType="Reference"&gt;1452893&lt;/ulink&gt;]. In July 2013, following the spin-out of  's    Covidien's pharmaceutical business, rights to OctreoScan  were presumed to have been transferred to newly formed   &lt;ulink linkID="1085756" linkType="Company"&gt;Mallinckrodt plc&lt;/ulink&gt; [&lt;ulink linkID="1446553" linkType="Reference"&gt;1446553&lt;/ulink&gt;]. In March 2015, Mallinckrodt's Japanese licensee &lt;ulink linkID="22616" linkType="Company"&gt;Fujifilm RI Pharma&lt;/ulink&gt; (now &lt;ulink linkID="22616" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="22616" linkType="Company"&gt;FUJIFILM Toyama Chemical Co Ltd&lt;/ulink&gt;, formed following the merger of Toyama Chemical and FUJIFILM RI Pharma Co Ltd) filed an application for approval of drug in Japan [&lt;ulink linkID="1671948" linkType="Reference"&gt;1671948&lt;/ulink&gt;], [&lt;ulink linkID="2077952" linkType="Reference"&gt;2077952&lt;/ulink&gt;]; in September 2015, the company received approval for the imaging agent in Japan [&lt;ulink linkID="1698531" linkType="Reference"&gt;1698531&lt;/ulink&gt;], [&lt;ulink linkID="1699628" linkType="Reference"&gt;1699628&lt;/ulink&gt;]; in November 2015, the product was approved for NHI price listing and was to be listed on November 26, 2015 [&lt;ulink linkID="1714823" linkType="Reference"&gt;1714823&lt;/ulink&gt;]; by October 2016, the drug had been launched in Japan [&lt;ulink linkID="2136114" linkType="Reference"&gt;2136114&lt;/ulink&gt;].  In December 2015, the launch was expected on January 27, 2016 [&lt;ulink linkID="1726764" linkType="Reference"&gt;1726764&lt;/ulink&gt;]. By February 2019, the drug had been launched in the Netherlands [&lt;ulink linkID="2136086" linkType="Reference"&gt;2136086&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 1994, the drug has been launched in the US [&lt;ulink linkID="205584" linkType="reference"&gt;205584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 1994, the drug was approved in the Czech Republic and was subsequently launched [&lt;ulink linkID="1447334" linkType="Reference"&gt;1447334&lt;/ulink&gt;], [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In June 1994, the drug has been launched in Europe [&lt;ulink linkID="205584" linkType="reference"&gt;205584&lt;/ulink&gt;]. In December 1994, the drug was approved in the Netherlands [&lt;ulink linkID="1430604" linkType="Reference"&gt;1430604&lt;/ulink&gt;]; by February 2019, the drug had been launched in the Netherlands [&lt;ulink linkID="2136086" linkType="Reference"&gt;2136086&lt;/ulink&gt;]. In March 1995, the drug was launched in France [&lt;ulink linkID="1351494" linkType="Reference"&gt;1351494&lt;/ulink&gt;]. In June 1995, the drug was approved in Ireland and was subsequently launched [&lt;ulink linkID="1398753" linkType="Reference"&gt;1398753&lt;/ulink&gt;]; at that time, the drug was approved in Denmark and was subsequently launched [&lt;ulink linkID="1426868" linkType="Reference"&gt;1426868&lt;/ulink&gt;]. In March 1997, the drug was launched in Switzerland [&lt;ulink linkID="1597316" linkType="Reference"&gt;1597316&lt;/ulink&gt;]. In November 1999, the drug was launched in Norway [&lt;ulink linkID="1458153" linkType="Reference"&gt;1458153&lt;/ulink&gt;]. In February 2006, the agent was approved in Belgium [&lt;ulink linkID="1449892" linkType="Reference"&gt;1449892&lt;/ulink&gt;]. In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1387664" linkType="Reference"&gt;1387664&lt;/ulink&gt;]. In October 2008, the drug was approved in Malta [&lt;ulink linkID="1452893" linkType="Reference"&gt;1452893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In March 2015, Fujifilm RI Pharma filed an application for approval for somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumor   [&lt;ulink linkID="1671948" linkType="Reference"&gt;1671948&lt;/ulink&gt;]. In August 2015, the drug application was recommended for approval by the second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council in Japan [&lt;ulink linkID="1690724" linkType="Reference"&gt;1690724&lt;/ulink&gt;]. In September 2015, following the discussion in the Review Committee on Unapproved Drugs and Indications with High Medical Needs, the company received approval for the imaging agent in Japan [&lt;ulink linkID="1698531" linkType="Reference"&gt;1698531&lt;/ulink&gt;], [&lt;ulink linkID="1699628" linkType="Reference"&gt;1699628&lt;/ulink&gt;]; in November 2015, the product was approved for NHI price listing and was to be listed on November 26, 2015 [&lt;ulink linkID="1714823" linkType="Reference"&gt;1714823&lt;/ulink&gt;]. In December 2015, the launch was expected on January 27, 2016 [&lt;ulink linkID="1726764" linkType="Reference"&gt;1726764&lt;/ulink&gt;]. By October 2016, the drug had been launched in Japan [&lt;ulink linkID="2136114" linkType="Reference"&gt;2136114&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2019-02-12T00:00:00.000Z</StatusDate><Source id="2136086" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><Source id="1398753" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2019-02-12T00:00:00.000Z</StatusDate><Source id="2136086" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-11-01T00:00:00.000Z</StatusDate><Source id="1458153" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17104">IMCERA Group Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1994-06-01T00:00:00.000Z</StatusDate><Source id="205584" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1997-03-15T00:00:00.000Z</StatusDate><Source id="1597316" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1994-06-01T00:00:00.000Z</StatusDate><Source id="205584" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2007-03-21T00:00:00.000Z</StatusDate><Source id="1387664" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1994-06-01T00:00:00.000Z</StatusDate><Source id="205584" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1995-03-19T00:00:00.000Z</StatusDate><Source id="1351494" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><Source id="1426868" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22616">FUJIFILM Toyama Chemical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2016-10-31T00:00:00.000Z</StatusDate><Source id="2136114" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><Source id="1444818" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085756">Mallinckrodt plc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2006-02-27T00:00:00.000Z</StatusDate><Source id="1449892" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17122">Mallinckrodt Medical</Company><Country id="MT">Malta</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2008-10-07T00:00:00.000Z</StatusDate><Source id="1452893" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17122">Mallinckrodt Medical</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1995-06-08T00:00:00.000Z</StatusDate><Source id="1398753" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17122">Mallinckrodt Medical</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1995-06-22T00:00:00.000Z</StatusDate><Source id="1426868" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17122">Mallinckrodt Medical</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1994-02-16T00:00:00.000Z</StatusDate><Source id="1447334" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22616">FUJIFILM Toyama Chemical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1671948" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17122">Mallinckrodt Medical</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1994-12-20T00:00:00.000Z</StatusDate><Source id="1430604" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085756">Mallinckrodt plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1446553" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22616">FUJIFILM Toyama Chemical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2015-09-27T00:00:00.000Z</StatusDate><Source id="1699628" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17122">Mallinckrodt Medical</OwnerCompany><Country id="US">US</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>Treatment of neuroendocrine tumors</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-06-16T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17122">Mallinckrodt Medical</OwnerCompany><Country id="US">US</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>Treatment of somatostatin receptor positive neuroendocrine tumors.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1999-06-10T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2136086" linkType="reference" linkID="2136086"&gt;2136086&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2136114" linkType="reference" linkID="2136114"&gt;2136114&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1037804">FUJIFILM Holdings Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1085756">Mallinckrodt plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1097361">Medtronic plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccccc4)NC(=O)[C@@H](Cc5ccccc5)NC(=O)CN6CCN7CCN(CC(=O)O[111In](OC(=O)C7)OC(=O)C6)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O</Smiles></StructureSmiles><Deals><Deal id="123267" title="Mallinckrodt Medical to develop Sandoz's OctreoScan in Europe, US, Middle East and Africa "/><Deal id="155026" title="FUJIFILM RI Pharma to develop and commercialize Indium In 111 pentetreotide from Mallinckrodt in Japan"/></Deals><PatentFamilies><PatentFamily id="1193580" number="WO-09006949" title="Peptide Derivatives"/><PatentFamily id="1870064" number="WO-09304702" title="Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins."/><PatentFamily id="206593" number="EP-00515313" title="Somatostatin analogues containing chelating groups and their radiolabeled compositions."/><PatentFamily id="2494407" number="WO-2013039916" title="Compositions for and methods of treatment and enhanced detection of non-pituitary tumors"/><PatentFamily id="496483" number="US-20080247947" title="High dose 111in-pentetreotide therapy of neuroendocrine tumors"/><PatentFamily id="571954" number="WO-03083074" title="Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="RadioMedix Inc" id="1042655"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mallinckrodt plc" id="1085756"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Goldman Sachs Lending Partners LLC" id="1093222"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medtronic plc" id="1097361"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Erasmus University Rotterdam" id="23277"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>